Suppression of CDCA3 inhibits prostate cancer progression via NF‑κB/cyclin D1 signaling inactivation and p21 accumulation

Gu,Peng; Zhang,Minhao; Zhu,Jin; He,Xiaoliang; Yang,Dongrong

doi:10.3892/or.2021.8253

Suppression of CDCA3 inhibits prostate cancer progression via NF‑κB/cyclin D1 signaling inactivation and p21 accumulation

Authors:
- Peng Gu
- Minhao Zhang
- Jin Zhu
- Xiaoliang He
- Dongrong Yang
View Affiliations

Affiliations: Department of Urology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China, Department of Urology, Xishan People's Hospital of Wuxi City, Wuxi, Jiangsu 214000, P.R. China
Published online on: December 28, 2021 https://doi.org/10.3892/or.2021.8253
Article Number: 42
Copyright: © Gu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysregulation of the cell cycle contributes to tumor progression. Cell division cycle‑associated 3 (CDCA3) is a known trigger of mitotic entry and has been demonstrated to be constitutively upregulated in tumors. It is therefore associated with carcinogenic properties reported in various cancers. However, the role of CDCA3 in prostate cancer is unclear. In the present study, western blotting and analysis of gene expression profiling datasets determined that CDCA3 expression was upregulated in prostate cancer and was associated with a poor prognosis. CDCA3 knockdown in DU145 and PC‑3 cells led to decreased cell proliferation and increased apoptosis, with increased protein expression levels of cleaved‑caspase3. Further experiments demonstrated that downregulated CDCA3 expression levels induced G0/G1 phase arrest, which was attributed to increased p21 protein expression levels and decreased cyclin D1 expression levels via the regulation of NF‑κB signaling proteins (NFκB‑p105/p50, IKKα/β, and pho‑NFκB‑p65). In conclusion, these results indicated that CDCA3 may serve a crucial role in prostate cancer and consequently, CDCA3 knockdown may be used as a potential therapeutic target.

View Figures

View References

1	Jin L, Zhou Y, Chen G, Dai G, Fu K, Yang D and Zhu J: EZH2-TROAP pathway promotes prostate cancer progression Via TWIST signals. Front Oncol. 10:5922392020. View Article : Google Scholar : PubMed/NCBI
2	Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG and de Bono JS: Prostate cancer. Lancet. 387:70–82. 2016. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
4	Wei B, Ruan J, Mi Y, Hu J, Zhang J, Wang Z, Hu Q, Jiang H and Ding Q: Knockdown of TNF receptor-associated factor 2 (TRAF2) modulates in vitro growth of TRAIL-treated prostate cancer cells. Biomed Pharmacother. 93:462–469. 2017. View Article : Google Scholar : PubMed/NCBI
5	De Angelis ML, Francescangeli F, La Torre F and Zeuner A: Stem cell plasticity and dormancy in the development of cancer therapy resistance. Front Oncol. 9:6262019. View Article : Google Scholar : PubMed/NCBI
6	Ahn JY, Hwang HS, Park YS, Kim HR, Jung HY, Kim JH, Lee SE and Kim MA: Endoscopic and pathologic findings associated with clinical outcomes of melanoma in the upper gastrointestinal tract. Ann Surg Oncol. 21:2532–2539. 2014. View Article : Google Scholar : PubMed/NCBI
7	Wu ZH, Fang M and Zhou Y: Comprehensive analysis of the expression and prognosis for CDCAs in head and neck squamous cell carcinoma. PLoS One. 15:e02366782020. View Article : Google Scholar : PubMed/NCBI
8	Phan NN, Wang CY, Li KL, Chen CF, Chiao CC, Yu HG, Huang PL and Lin YC: Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient. Oncotarget. 9:6977–6992. 2018. View Article : Google Scholar : PubMed/NCBI
9	Obara W, Sato F, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Mimata H, Sugai T, Nakamura Y and Fujioka T: Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci. 108:1452–1457. 2017. View Article : Google Scholar : PubMed/NCBI
10	Zhang Y, Cheng Y, Zhang Z, Bai Z, Jin H, Guo X, Huang X, Li M, Wang M, Shu XS, et al: CDCA2 inhibits apoptosis and promotes cell proliferation in prostate cancer and is directly regulated by HIF-1α pathway. Front Oncol. 10:7252020. View Article : Google Scholar : PubMed/NCBI
11	Clermont PL, Crea F, Chiang YT, Lin D, Zhang A, Wang JZ, Parolia A, Wu R, Xue H, Wang Y, et al: Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clin Epigenetics. 8:162016. View Article : Google Scholar : PubMed/NCBI
12	Song Z, Huang Y, Zhao Y, Ruan H, Yang H, Cao Q, Liu D, Zhang X and Chen K: The identification of potential biomarkers and biological pathways in prostate cancer. J Cancer. 10:1398–1408. 2019. View Article : Google Scholar : PubMed/NCBI
13	Qian W, Zhang Z, Peng W, Li J, Gu Q, Ji D, Wang Q, Zhang Y, Ji B, Wang S, et al: CDCA3 mediates p21-dependent proliferation by regulating E2F1 expression in colorectal cancer. Int J Oncol. 53:2021–2033. 2018.PubMed/NCBI
14	Zhang W, Lu Y and Li X, Zhang J, Zheng L, Zhang W, Lin C, Lin W and Li X: CDCA3 promotes cell proliferation by activating the NF-κB/cyclin D1 signaling pathway in colorectal cancer. Biochem Biophys Res Commun. 500:196–203. 2018. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Yin W, Cao W, Chen P, Bian L and Ni Q: CDCA3 is a potential prognostic marker that promotes cell proliferation in gastric cancer. Oncol Rep. 41:2471–2481. 2019.PubMed/NCBI
16	Adams MN, Burgess JT, He Y, Gately K, Snell C, Zhang SD, Hooper JD, Richard DJ and O'Byrne KJ: Expression of CDCA3 Is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer. J Thorac Oncol. 12:1071–1084. 2017. View Article : Google Scholar : PubMed/NCBI
17	Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Bukawa H: Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest. BMC Cancer. 12:3212012. View Article : Google Scholar : PubMed/NCBI
18	Zou RC, Guo ZT, Wei D, Shi ZT, Ye ZC, Zhai G, Zhong C, Tang B, Wang L and Ge JY: Downregulation of CDCA3 expression inhibits tumor formation in pancreatic cancer. Neoplasma. 67:1223–1232. 2020. View Article : Google Scholar : PubMed/NCBI
19	Chen J, Zhu S, Jiang N, Shang Z, Quan C and Niu Y: HoxB3 promotes prostate cancer cell progression by transactivating CDCA3. Cancer Lett. 330:217–224. 2013. View Article : Google Scholar : PubMed/NCBI
20	Liu L, Guo K, Liang Z, Li F and Wang H: Identification of candidate genes that may contribute to the metastasis of prostate cancer by bioinformatics analysis. Oncol Lett. 15:1220–1228. 2018.PubMed/NCBI
21	Guo L, Liu Y, Ding Z, Sun W and Yuan M: Signal transduction by M3 muscarinic acetylcholine receptor in prostate cancer. Oncol Lett. 11:385–392. 2016. View Article : Google Scholar : PubMed/NCBI
22	Gu P, Yang D, Zhu J, Zhang M and He X: Bioinformatics analysis identified hub genes in prostate cancer tumorigenesis and metastasis. Math Biosci Eng. 18:3180–3196. 2021. View Article : Google Scholar : PubMed/NCBI
23	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
24	Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and Lin CY: cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 8 (Suppl 4):S112014. View Article : Google Scholar : PubMed/NCBI
25	Zhou Y, Gu P, Li J, Li F, Zhu J, Gao P, Zang Y, Wang Y, Shan Y and Yang D: Suppression of STIM1 inhibits the migration and invasion of human prostate cancer cells and is associated with PI3K/Akt signaling inactivation. Oncol Rep. 38:2629–2636. 2017. View Article : Google Scholar : PubMed/NCBI
26	Qie S and Diehl JA: Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl). 94:1313–1326. 2016. View Article : Google Scholar : PubMed/NCBI
27	Ma T, Chen H, Wang P, Yang N and Bao J: Downregulation of lncRNA ZEB1-AS1 represses cell proliferation, migration, and invasion through mediating PI3K/AKT/mTOR signaling by miR-342-3p/CUL4B Axis in prostate cancer. Cancer Biother Radiopharm. 35:661–672. 2020. View Article : Google Scholar : PubMed/NCBI
28	Nguyen DP, Li J, Yadav SS and Tewari AK: Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer. BJU Int. 114:168–176. 2014. View Article : Google Scholar : PubMed/NCBI
29	Dominska K, Kowalska K, Matysiak ZE, Pluciennik E, Ochedalski T and Piastowska-Ciesielska AW: Regulation of mRNA gene expression of members of the NF-κB transcription factor gene family by angiotensin II and relaxin 2 in normal and cancer prostate cell lines. Mol Med Rep. 15:4352–4359. 2017. View Article : Google Scholar : PubMed/NCBI
30	Ji J, Shen T, Li Y, Liu Y, Shang Z and Niu Y: CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway. Oncol Rep. 45:921–932. 2021. View Article : Google Scholar : PubMed/NCBI
31	Zheng P, Wu K, Gao Z, Li H, Li W, Wang X, Shi Z, Xiao F, Wang K, Li Z and Han Q: KIF4A promotes the development of bladder cancer by transcriptionally activating the expression of CDCA3. Int J Mol Med. 47:992021. View Article : Google Scholar : PubMed/NCBI
32	Bi L, Zhou B, Li H, He L, Wang C, Wang Z, Zhu L, Chen M and Gao S: A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia. BMC Cancer. 18:1822018. View Article : Google Scholar : PubMed/NCBI
33	Liu Y, Cheng G, Huang Z, Bao L, Liu J, Wang C, Xiong Z, Zhou L, Xu T, Liu D, et al: Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma. Cell Death Dis. 11:5152020. View Article : Google Scholar : PubMed/NCBI
34	Jin M, Duan J, Liu W, Ji J, Liu B and Zhang M: Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells. Cancer Cell Int. 21:1912021. View Article : Google Scholar : PubMed/NCBI
35	Jung AR, Kim GE, Kim MY, Ha US, Hong SH, Lee JY, Kim SW and Park YH: HMGB1 promotes tumor progression and invasion through HMGB1/TNFR1/NF-κB axis in castration-resistant prostate cancer. Am J Cancer Res. 11:2215–2227. 2021.PubMed/NCBI
36	Staal J and Beyaert R: Inflammation and NF-κB signaling in prostate cancer: Mechanisms and clinical implications. Cells. 7:1222018. View Article : Google Scholar : PubMed/NCBI
37	He S, Chen M, Lin X, Lv Z, Liang R and Huang L: Triptolide inhibits PDGF-induced proliferation of ASMCs through G0/G1 cell cycle arrest and suppression of the AKT/NF-κB/cyclinD1 signaling pathway. Eur J Pharmacol. 867:1728112020. View Article : Google Scholar : PubMed/NCBI
38	Zhang R, Li J, Yan X, Jin K, Li W, Liu X, Zhao J, Shang W and Zhao X: Long noncoding RNA MLK7AS1 promotes proliferation in human colorectal cancer via downregulation of p21 expression. Mol Med Rep. 19:1210–1221. 2019.PubMed/NCBI
39	Cui X, Cui M, Asada R, Kanemoto S, Saito A, Matsuhisa K, Kaneko M and Imaizumi K: The androgen-induced protein AIbZIP facilitates proliferation of prostate cancer cells through downregulation of p21 expression. Sci Rep. 6:373102016. View Article : Google Scholar : PubMed/NCBI PubMed/NCBI